AbCellera Biologics Inc.
ABCL
$3.85
$0.071.85%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 39.10% | -34.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.10% | -34.38% | |||
| Cost of Revenue | -351.22% | 3.96% | |||
| Gross Profit | 433.46% | -18.55% | |||
| SG&A Expenses | 6.94% | -7.88% | |||
| Depreciation & Amortization | 31.40% | 2.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.35% | 0.07% | |||
| Operating Income | -20.34% | -6.81% | |||
| Income Before Tax | -23.74% | -3.35% | |||
| Income Tax Expenses | 86.39% | -42.67% | |||
| Earnings from Continuing Operations | -64.80% | 6.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -64.80% | 6.28% | |||
| EBIT | -20.34% | -6.81% | |||
| EBITDA | -19.05% | -7.37% | |||
| EPS Basic | -64.37% | 6.53% | |||
| Normalized Basic EPS | -17.90% | -15.37% | |||
| EPS Diluted | -69.80% | 9.09% | |||
| Normalized Diluted EPS | -17.90% | -15.37% | |||
| Average Basic Shares Outstanding | 0.32% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
